HomeAI · summaries
Storia in 5 fonti
FDA expands Pluvicto label, making it available to most metastatic prostate cancer patients
It’s an important nod for Novartis, which has bet big on the radiopharmaceutical industry. The approval nearly doubles the eligible patient population for Pluvicto.
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
FDA approves Pluvicto for PSMA-positive metastatic hormone-sensitive prostate cancer
The FDA has expanded approval for a radioligand therapy that nearly doubles the number of men with advanced prostate cancer eligible to receive the treatment, according to a…
- ·
fiercepharma.com
Novartis' Pluvicto leaps ahead into earlier manifestation of prostate cancer
Novartis’ blockbuster radioligand therapy Pluvicto has cleared a key milestone on its quest to hit $5 billion in peak sales, securing a U.S. | Novartis’ blockbuster radioligand…
